CURI vs PUBM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

CURI

41.0
AI Score
VS
CURI Wins

PUBM

29.7
AI Score

Investment Advisor Scores

CURI

41score
Recommendation
HOLD

PUBM

30score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric CURI PUBM Winner
Forward P/E 13.7741 53.4759 CURI
PEG Ratio 0 5.3444 Tie
Revenue Growth 22.3% 10.5% CURI
Earnings Growth 1400.0% -49.5% CURI
Tradestie Score 41.0/100 29.7/100 CURI
Profit Margin 0.0% -4.7% CURI
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL CURI

Relative Price Performance (Last 90 Days)

CURI 1M: +20.9% · 3M: +11.4% PUBM 1M: +30.7% · 3M: +57.9%

Current Technical Phase

CURI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $2.84

PUBM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (15.4% over 20 days), RSI 61

RSI (14): 60.8 · Price: $16.36

Fundamentals Snapshot

Metric CURI PUBM
Market Cap
Forward P/E 9.2 20.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.2% 0.1%
Gross Margin 0.6% 0.6%
Operating Margin 0.4% 0.0%
EPS -0.01 -0.29
Dividend Yield 0.11%

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.